<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377674</url>
  </required_header>
  <id_info>
    <org_study_id>XEL-CR-05</org_study_id>
    <nct_id>NCT02377674</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection</brief_title>
  <acronym>EC-TCPC</acronym>
  <official_title>To Assess the Initial Safety and Performance of COR-VG-001 Conduit in Pediatric Patients Undergoing Extracardiac Total Cavopulmonary Connection (EC-TCPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeltis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technomics Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeltis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The extracardiac Fontan surgery/procedure involves diverting the venous blood from the&#xD;
      inferior vena cava to the pulmonary arteries without passing through the morphologic right&#xD;
      ventricle. In the extracardiac conduit type of Fontan, one end of a synthetic tube graft is&#xD;
      connected to the inferior vena cava and the other end to the pulmonary artery confluence.&#xD;
&#xD;
      Xeltis developed a biodegradable prosthesis, the Xeltis Vascular Graft Model COR-VG-001, to&#xD;
      be used as an extracardiac conduit between right atrium and the pulmonary arteries. The&#xD;
      prosthesis is immediately mechanically functional, while its physiochemical characteristics&#xD;
      should enable cell infiltration and tissue formation.&#xD;
&#xD;
      The Xeltis Vascular Graft Model COR-VG-OO is specifically designed to enhance the Fontan&#xD;
      surgery outcome by reducing synthetic material related complications and improving&#xD;
      hemodynamic characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although significant progress has been made in recent years in the field of congenital heart&#xD;
      disease treatment, a substantial unmet clinical need remains for implantable&#xD;
      materials/devices such as vascular grafts and heart valves with improved long-term&#xD;
      performance and reduced device-related complications.&#xD;
&#xD;
      To address these limitations new generation of biodegradable polymers using recent advances&#xD;
      in supramolecular chemistry have been developed to create highly porous vascular grafts&#xD;
      allowing efficient cell infiltration following by gradual replacement of the polymer material&#xD;
      with the patient's own native-like vascular tissue resulting in full functional restoration.&#xD;
      In addition to the ability of reducing postoperative graft-related complications such types&#xD;
      of implants have a potential to grow to adapt to the overall body growth and therefore may&#xD;
      represent a completely new modality for the treatment of congenital heart disease. In&#xD;
      contrast to today's situation with synthetic non-absorbable vascular grafts considered as a&#xD;
      &quot;standard of care&quot;, where the pediatric patients have to be re-operated several times to&#xD;
      adjust the prosthesis size to the somatic growth of the child associated with substantial&#xD;
      morbidity and mortality and requiring prolonged anticoagulation treatment, a biodegradable&#xD;
      polymer implant could represent a &quot;one-time solution&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the safety of the COR-VG-001 as defined by numbers of patients having graft related post-operative complications requiring surgery, intervention or leading to death within 12-month post implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Grafts That Have a Reduced Function Post Operatively.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the performance of the COR-VG-01 by analyzing, with the help of echocardiography, the incidence of loss of functionality requiring intervention within 12 months post implantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>Vascular Graft, Model COR-VG-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular Graft, Model COR-VG-001</intervention_name>
    <description>The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
    <arm_group_label>Vascular Graft, Model COR-VG-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient requiring EC-TCPC&#xD;
&#xD;
          2. Male or Female&#xD;
&#xD;
          3. Aged ≥ 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pulmonary artery pressure (PAP) &gt; 15 mm Hg as excluded by angiography/cardiac&#xD;
             catheterization&#xD;
&#xD;
          2. Pulmonary vascular resistance (PVR) &gt;3 Wood units as excluded by angiography/cardiac&#xD;
             catheterization&#xD;
&#xD;
          3. Moderate or severe atrioventricular (AV) valve regurgitation requiring correction, as&#xD;
             determined by echocardiography and/or angiography&#xD;
&#xD;
          4. Moderate or severe outflow valve regurgitation requiring correction as determined by&#xD;
             echocardiography and/or angiography&#xD;
&#xD;
          5. Outflow tract (aortic arch and isthmus) obstruction as excluded by:&#xD;
&#xD;
               -  a residual outflow gradient of ≥ 20mm Hg or&#xD;
&#xD;
               -  requirement of corrective surgery&#xD;
&#xD;
               -  as determined by echocardiography and/ or angiography&#xD;
&#xD;
          6. All arrhythmias as determined by ECG and/or at the investigator's discretion&#xD;
&#xD;
          7. Renal dysfunction as excluded by serum creatinine &gt; ULN and/or urea &gt;ULN and/or at the&#xD;
             investigator's discretion&#xD;
&#xD;
          8. Hepatic dysfunction as excluded by ALT &gt;ULN, AST &gt; ULN, GGT &gt; ULN and/or at the&#xD;
             investigator's discretion&#xD;
&#xD;
          9. Coagulation disorders as defined by INR outside its normal value, PTT &gt;ULN and&#xD;
             Fibrinogen &lt;LLN and/or at the investigator's discretion&#xD;
&#xD;
         10. Transcutaneous O2 saturation &lt; 65% and/or at the investigator's discretion&#xD;
&#xD;
         11. Immunodeficiency&#xD;
&#xD;
         12. Trisomia 21&#xD;
&#xD;
         13. Asplenia as determined by abdominal ultrasound&#xD;
&#xD;
         14. Heterotaxia as determined by abdominal ultrasound&#xD;
&#xD;
         15. HIV-infection&#xD;
&#xD;
         16. Syphilis (Treponema pallidum)&#xD;
&#xD;
         17. Hepatitis-B and/or -C virus infection&#xD;
&#xD;
         18. Unwillingness of Parental/legal guardian to give consent&#xD;
&#xD;
         19. Contraindications on ethical grounds&#xD;
&#xD;
         20. Treatment with other investigational products&#xD;
&#xD;
         21. Known or suspected non-compliance, drug or alcohol abuse of the parents/legal guardian&#xD;
&#xD;
         22. Inability of the parents/legal guardian to follow the procedures of the study, e.g.&#xD;
             due to language problems&#xD;
&#xD;
         23. Participation of the patient in another study within 30 days preceding and during the&#xD;
             present study&#xD;
&#xD;
         24. Previous enrollment of the patient into the current study&#xD;
&#xD;
         25. Enrollment of the investigator's family members, employees and other dependent persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Bockeria, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bakoulev Center of Cardiovascular Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bakoulev Center of Cardiovascular Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vascular Graft, Model COR-VG-001</title>
          <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.&#xD;
Vascular Graft, Model COR-VG-001: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vascular Graft, Model COR-VG-001</title>
          <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.&#xD;
Vascular Graft, Model COR-VG-001: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation.</title>
        <description>Evaluation of the safety of the COR-VG-001 as defined by numbers of patients having graft related post-operative complications requiring surgery, intervention or leading to death within 12-month post implantation</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vascular Graft, Model COR-VG-001</title>
            <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.&#xD;
Vascular Graft, Model COR-VG-001: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation.</title>
          <description>Evaluation of the safety of the COR-VG-001 as defined by numbers of patients having graft related post-operative complications requiring surgery, intervention or leading to death within 12-month post implantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Grafts That Have a Reduced Function Post Operatively.</title>
        <description>Evaluation of the performance of the COR-VG-01 by analyzing, with the help of echocardiography, the incidence of loss of functionality requiring intervention within 12 months post implantation.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vascular Graft, Model COR-VG-001</title>
            <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.&#xD;
Vascular Graft, Model COR-VG-001: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Grafts That Have a Reduced Function Post Operatively.</title>
          <description>Evaluation of the performance of the COR-VG-01 by analyzing, with the help of echocardiography, the incidence of loss of functionality requiring intervention within 12 months post implantation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vascular Graft, Model COR-VG-001</title>
          <description>A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.&#xD;
Vascular Graft, Model COR-VG-001: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure, poly seriositis NYHA III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased LVEF</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Left Lower Lobe Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Stenosis of Conduit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion Caused by Cardiac Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Onset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased Ejection Fraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Low Stroke Volume in the IVC and Conduit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mild Stenosis In Conduit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Reduced Maximum Systolic Velocity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Researchers engaged in Project can present research results provided the Sponsor has been furnished copies at least one month in advance of the submission. Sponsor shall have thirty (30) days, after receipt of said copies, to object because there is confidential subject matter or proprietary information of Sponsor which needs protection. In the event that Sponsor makes such objection, said Researcher(s) shall refrain from making such publication or presentation for a maximum of six months</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eliane Schutte, CEO</name_or_title>
      <organization>Xeltis</organization>
      <phone>+31 40 751 7614</phone>
      <email>clinical@xeltis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

